Midatech Pharma (MTP) Stock Rockets On Partnership News

MidaTech Pharma MTP Stock News

Midatech Pharma PLC-ADR (NASDAQ: MTP) stock is flying in the market this morning, trading on gains that are better represented in multiples than percentages. While a search on Yahoo! Finance will yield no new news, a search on the SEC website will show that the company has entered into a partnership. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

MTP Rockets On Partnership

In the SEC filing, Midatech Pharma said that it has entered into a research collaboration with a European affiliate of a global pharmaceutical company. The partnership surrounds the use of the company’s Q-Sphera platform.

In the filing, MTP said that the collaboration will involve multiple projects. Within these projects, the company will deploy its in-house expertise and proprietary drug delivery platforms toward assets nominated by the pharmaceutical company.

It is expected that the feasibility studies under this partnership will establish the application of the Q-Sphera platform to new modalities in drug delivery. Should the feasibility study be successful, the pharmaceutical company has agreed to enter into a license agreement for the use of the Q-Sphera platform.

In the filing, the company explained that this is the second pharmaceutical collaboration surrounding the Q-Sphera platform, further validating the company’s work. In a statement, Stephen Stamp, CEO at MTP, had the following to offer:

This collaboration with a highly reputable company further builds upon Midatech’s mission to use our expertise and established capabilities to continually innovate and improve our technologies. By furthering our collaborative business model, we believe we can enable the unique qualities of this technology to reach beyond our own internal development pipeline for the benefit of all patients.

This News Is Huge

The news issued by Midatech Pharma today proved to be overwhelmingly positive. Afterall, the company has invested massive amounts of time and money into the development of the Q-Sphera platform.

With multiple pharmaceutical companies now seeing value in the platform, the company’s work is further validated. Moreover, as the results of feasibility studies come down the line, there’s a strong chance that the company will see significant licensing revenues, making MTP stock one worth watching!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.